Abstract
WuXi Biologics will purchase a Bayer plant for finished biologic drugs in Leverkusen, Germany. In addition to being used by the Chinese pharmaceutical services firm, the plant will be a backup site for making Bayer’s Kovaltry, a recombinant antihemophilic factor. From its base in China, WuXi Biologics has expanded rapidly in recent years. It is building a $60 million biologics plant in Worcester, Massachusetts, and a $390 million facility in Dundalk, Ireland.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
